Fig. 4.

Plasma EV proteomic identification and quantitation by TMT carrier strategy to describe the regulation of ADME proteins from vehicle controls (n = 3) and rifampicin treatment trials (n = 3). A) Classification of identified plasma EV proteins in TMT carrier experiments based on biological process, emphasizing that multiple liver-focused metabolic processes were enriched with liver tissue EV as TMT carrier. As our focus, 13 ADME proteins showed significant upregulation average, including B) six proteins within P450 family and C) seven proteins beyond P450. Meanwhile, the other 21 ADME proteins showed rifampicin-causing upregulation <30% D), with “vehicle” trials in dash lines and “rifampicin” trials in solid lines.